Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Sepracor Disputes Patent on Wyeth’s Pristiq

By Pharmaceutical Processing | April 17, 2009

NEW YORK (AP) — Sepracor Inc. on Friday took a step toward a potential challenge of patents supporting Pristiq, an antidepressant marketed by Wyeth. Sepracor says it discovered the drug first and filed an application for a patent in April 1999, almost two years before Wyeth made its first filing in February 2001. The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office plans to hear arguments from the two companies on Jan. 6, 2010. Sepracor says the patent interference is between two patents awarded to Wyeth, and three given to Sepracor. The board will rule on who invented the drug first and who will hold the patents. If the board rules in favor of Sepracor, it could be awarded a patent on Pristiq and potentially sue Wyeth for patent infringement. Doug Petkus, a spokesman for Wyeth, said his employer would win the challenge. “Wyeth will prove during the upcoming proceedings before the patent office that we invented desvenlafaxine and that Sepracor’s position is without merit,” he said. Marlborough, Mass.-based Sepracor calls the chemical O-desmethylvenlafaxine succinate, and Wyeth, of Madison, N.J., uses the name desvenlafaxine. Wyeth began selling Pristiq in February 2008, and some Wall Street analysts believe it could be a replacement for the multi-billion-selling depression treatment Effexor. Worldwide sales totaled $66.5 million last year. Wyeth agreed to sell itself to larger rival Pfizer Inc. in January, in a deal valued at $68 billion.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards